Stifel analyst Laura Prendergast raised the firm’s price target on Erasca (ERAS) to $20 from $10 and keeps a Buy rating on the shares. The firm’s new price target assumes ERAS-0015 data in 1H26 will look slightly differentiated to Revolution Medicines’ (RVMD) early daraxonrasib safety/efficacy, the analyst tells investors in a research note. The firm added that it models Erasca generating roughly $3.2B in global revenue by 2035.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca exercises option to secure worldwide rights for ERAS-0015
- Erasca added to ‘Positive Catalyst Watch list’ at JPMorgan
- Compelling Risk‑Reward in Erasca’s RAS/MAPK Pipeline Ahead of Key ERAS-0015 2026 Readout
- Tango Therapeutics price target raised to $20 from $18 at Guggenheim
- Erasca price target raised to $20 from $11 at Clear Street